Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
SVB Leerink Presentation Feb 24, 2021
Corporate Deck February 2021
Corporate Deck January 2021
JPM Presentation Jan 14, 2021
Investor Deck December 2020
Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020
Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
Press Releases
ObsEva Announces Year End 2020 Financial Results and Business Update
press release
March 5, 2021
-Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21- -Yselty® for…
Read moreObsEva to Present at the H.C. Wainwright Global Life Sciences Conference
press release
March 3, 2021
Geneva, Switzerland and Boston, MA – March 3, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…
Read moreObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
press release
February 17, 2021
Geneva, Switzerland and Boston, MA – February 17, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2020
June 9, 2020
ObsEva Annual General Meeting 2019
May 8, 2019
Upcoming Events
Stock Information
Latest Press Release
ObsEva Announces First Quarter 2021 Financial Results and Business Update
-Yselty® for uterine fibroids: US New Drug Application submission planned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Yselty®…
Read moreInvestor Contact
Media Contact
Media Switzerland & Europe
Shauna Dillon
+41 (0)22 552 1550 Office
+41 79 360 3533 Mobile
Media United States
Shauna Dillon
+41 (0)22 552 1550 Office
+41 (0)79 360 3533 Mobile
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Media Switzerland & Europe
Shauna Dillon
+41 (0)22 552 1550 Office
+41 79 360 3533 Mobile
Media United States
Shauna Dillon
+41 (0)22 552 1550 Office
+41 (0)79 360 3533 Mobile
Sign up for news
